rethinkTHC Search
Menu
Study breakdown

CBD Shows Antibacterial Activity Against Drug-Resistant Hospital Bacteria

Laboratory AnalysisPreliminary evidence
The takeaway

CBD demonstrated antibacterial effects against all tested Enterococcus strains, including drug-resistant hospital pathogens, at very low concentrations.

Microbiologists, infectious disease researchers, antimicrobial resistance specialists

What the researchers found

CBD displayed antibacterial properties against all 20 tested clinical strains of E. faecalis and E. faecium with MIC values at or below 1 μg/mL. Higher CBD concentrations produced stronger antibacterial effects. Pure CBD and CBD crystals showed statistically lower MICs than CBD oils. E. faecium was more susceptible than E. faecalis.

Why it matters

Enterococcus bacteria are increasingly resistant to conventional antibiotics and cause serious hospital infections. Finding that CBD works against these multidrug-resistant strains at low concentrations opens a potential new avenue in the fight against antibiotic resistance.

The numbers in context

MIC ≤ 1 μg/mL for all tested strains. 20 clinical strains tested (E. faecalis and E. faecium). 5 CBD oils and 1 CBD crystal product (99% purity) evaluated. Pure CBD significantly more effective than CBD oils.

How the study worked

Pilot study evaluating antimicrobial effects of five CBD oils and one 99% CBD crystal product against 20 clinical strains of Enterococcus species using the microdilution method in Mueller-Hinton broth to determine Minimal Inhibitory Concentrations.

What this study cannot tell us

In vitro pilot study only — lab conditions don't reflect the complexity of treating infections in living organisms. Small number of strains tested. Mechanism of antibacterial action not elucidated. No toxicity or pharmacokinetic data.

How to read the evidence

Pilot in vitro study demonstrates clear antibacterial activity but is far from clinical application. Mechanism and in vivo efficacy unknown.

When this study was published

Published 2026, addressing the growing multidrug-resistant Enterococcus crisis.

The bigger picture

Antibiotic resistance is one of the greatest threats to global health. CBD's antibacterial properties against hospital superbugs suggest cannabinoids could become part of future antimicrobial arsenals — though significant development work remains.

Questions still open

  • What is CBD's mechanism of antibacterial action against Enterococcus? Would CBD work synergistically with existing antibiotics? Could CBD-based topical formulations prevent surgical site infections?

Common questions

Can CBD kill bacteria?
In lab tests, CBD inhibited the growth of all 20 drug-resistant Enterococcus bacteria strains at very low concentrations. However, this is a pilot lab study — it hasn't been tested as a treatment for actual infections.
Is CBD oil as effective as pure CBD against bacteria?
No — pure CBD crystals (99% purity) showed significantly stronger antibacterial effects than CBD oils, suggesting the concentration and purity of CBD matters for antimicrobial activity.

Read the original research

Cannabidiol (CBD) and Other Cannabinoids as a Promising Alternative Antibacterial Agent-Pilot Study on Enterococcus faecalis and Enterococcus faecium Clinical Strains.

Molecules (Basel, Switzerland), 31(1)

Citation

Kraszewska, Zuzanna; Grudlewska-Buda, Katarzyna; Wnuk, Kacper; Wałecka-Zacharska, Ewa; Gospodarek-Komkowska, Eugenia; Skowron, Krzysztof. (2026). Cannabidiol (CBD) and Other Cannabinoids as a Promising Alternative Antibacterial Agent-Pilot Study on Enterococcus faecalis and Enterococcus faecium Clinical Strains.. Molecules (Basel, Switzerland), 31(1). https://doi.org/10.3390/molecules31010144

Explore the wider topic